SG10201406178WA - Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors - Google Patents
Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptorsInfo
- Publication number
- SG10201406178WA SG10201406178WA SG10201406178WA SG10201406178WA SG10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA SG 10201406178W A SG10201406178W A SG 10201406178WA
- Authority
- SG
- Singapore
- Prior art keywords
- sphingosine
- subtype
- receptors
- phosphate
- condensed ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24664209P | 2009-09-29 | 2009-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201406178WA true SG10201406178WA (en) | 2014-11-27 |
Family
ID=43031503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201406178WA SG10201406178WA (en) | 2009-09-29 | 2010-09-28 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8507682B2 (en) |
| EP (1) | EP2483245A1 (en) |
| JP (1) | JP2013506003A (en) |
| KR (1) | KR20120087932A (en) |
| CN (1) | CN102741232A (en) |
| AU (1) | AU2010300791A1 (en) |
| BR (1) | BR112012007095A2 (en) |
| CA (1) | CA2775587A1 (en) |
| IL (1) | IL218843A0 (en) |
| MX (1) | MX2012003718A (en) |
| NZ (1) | NZ599595A (en) |
| RU (1) | RU2012114718A (en) |
| SG (1) | SG10201406178WA (en) |
| WO (1) | WO2011041287A1 (en) |
| ZA (1) | ZA201202366B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9663511B2 (en) * | 2012-03-26 | 2017-05-30 | Arroyo BioSciences, LLC | Sphingosine 1-phosphate receptor antagonists |
| WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
| CA2953208C (en) | 2014-06-02 | 2022-05-10 | Dalhousie University | Treatment of familial exudative vitreoretinopathy through s1pr2 inhibition |
| CN107849038A (en) * | 2015-06-01 | 2018-03-27 | 达尔豪西大学 | S1PR2 antagonists and application thereof |
| US10858358B2 (en) | 2015-06-01 | 2020-12-08 | Dalhousie University | S1PR2 antagonists and uses therefor |
| US10487082B2 (en) | 2015-06-01 | 2019-11-26 | Dalhousie University | S1PR2 antagonists and uses therefor |
| CN107382965A (en) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | The synthetic method of the receptor stimulating agent drug molecules of new S1P 1 with antitumor activity |
| CN113896646B (en) * | 2020-07-06 | 2023-06-02 | 浙江海森药业股份有限公司 | Efficient green preparation method of 4-methyl-3-oxo-N-phenyl valeramide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0146810A3 (en) | 1983-12-05 | 1987-05-13 | Solco Basel AG | Process for the preparation of sphingosin derivatives |
| US5110987A (en) | 1988-06-17 | 1992-05-05 | Emory University | Method of preparing sphingosine derivatives |
| ZA902794B (en) | 1989-04-18 | 1991-04-24 | Duphar Int Res | New 3-n substituted carbamoyl-indole derivatives |
| US5294722A (en) | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
| US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
| ATE314342T1 (en) | 1997-03-12 | 2006-01-15 | Takara Bio Inc | SPINGOSINE ANALOGUE |
| WO1999012890A1 (en) | 1997-09-11 | 1999-03-18 | Takara Shuzo Co., Ltd. | Sphingosine derivatives and medicinal composition |
| WO2001098301A1 (en) * | 2000-06-20 | 2001-12-27 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| US20020183762A1 (en) | 2001-06-01 | 2002-12-05 | Ams Research Corporation | Bone anchor inserters and methods |
| JP4399253B2 (en) | 2001-06-20 | 2010-01-13 | ワイス | Substituted indoleic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| WO2003020313A1 (en) * | 2001-09-04 | 2003-03-13 | Ono Pharmaceutical Co., Ltd. | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| JPWO2003051876A1 (en) * | 2001-12-14 | 2005-04-28 | 日本たばこ産業株式会社 | Pyrazolopyridine derivatives and pharmaceutical use thereof |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| TW200406385A (en) | 2002-05-31 | 2004-05-01 | Eisai Co Ltd | Pyrazole compound and pharmaceutical composition containing the same |
| WO2008154470A1 (en) | 2007-06-08 | 2008-12-18 | University Of Connecticut | Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye |
| WO2009074969A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Lausanne | Sphingosine-1-phosphate, analogs and antagonists for use as medicaments |
-
2010
- 2010-09-28 CA CA2775587A patent/CA2775587A1/en not_active Abandoned
- 2010-09-28 WO PCT/US2010/050486 patent/WO2011041287A1/en active Application Filing
- 2010-09-28 KR KR1020127010718A patent/KR20120087932A/en not_active Application Discontinuation
- 2010-09-28 SG SG10201406178WA patent/SG10201406178WA/en unknown
- 2010-09-28 NZ NZ599595A patent/NZ599595A/en not_active IP Right Cessation
- 2010-09-28 AU AU2010300791A patent/AU2010300791A1/en not_active Abandoned
- 2010-09-28 US US13/498,499 patent/US8507682B2/en not_active Expired - Fee Related
- 2010-09-28 EP EP10763267A patent/EP2483245A1/en not_active Withdrawn
- 2010-09-28 CN CN2010800492699A patent/CN102741232A/en active Pending
- 2010-09-28 JP JP2012532230A patent/JP2013506003A/en active Pending
- 2010-09-28 RU RU2012114718/04A patent/RU2012114718A/en not_active Application Discontinuation
- 2010-09-28 BR BR112012007095A patent/BR112012007095A2/en not_active IP Right Cessation
- 2010-09-28 MX MX2012003718A patent/MX2012003718A/en active IP Right Grant
-
2012
- 2012-03-26 IL IL218843A patent/IL218843A0/en unknown
- 2012-04-02 ZA ZA2012/02366A patent/ZA201202366B/en unknown
-
2013
- 2013-06-27 US US13/929,451 patent/US8703797B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120087932A (en) | 2012-08-07 |
| WO2011041287A1 (en) | 2011-04-07 |
| RU2012114718A (en) | 2013-11-10 |
| JP2013506003A (en) | 2013-02-21 |
| US8703797B2 (en) | 2014-04-22 |
| BR112012007095A2 (en) | 2016-04-19 |
| ZA201202366B (en) | 2012-12-27 |
| AU2010300791A1 (en) | 2012-04-19 |
| US8507682B2 (en) | 2013-08-13 |
| MX2012003718A (en) | 2012-06-28 |
| CA2775587A1 (en) | 2011-04-07 |
| EP2483245A1 (en) | 2012-08-08 |
| IL218843A0 (en) | 2012-06-28 |
| US20120208840A1 (en) | 2012-08-16 |
| NZ599595A (en) | 2014-03-28 |
| US20130296361A1 (en) | 2013-11-07 |
| CN102741232A (en) | 2012-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201202366B (en) | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors | |
| IL238849A (en) | Process for preparation of c-met modulating compounds | |
| IL232112A0 (en) | Novel substituted imidazopyrimidines as gpbar1 receptor modulators | |
| ZA201303421B (en) | Compounds useful as modulators of trpm8 | |
| HK1175461A1 (en) | Fused heterocyclic compounds as orexin receptor modulators (orexin) | |
| HK1175462A1 (en) | Fused heterocyclic compounds as orexin receptor modulators | |
| EP2599774A4 (en) | Condensed ring pyridine compound | |
| EP2583965A4 (en) | Heterocyclic ring compound | |
| EP2776411A4 (en) | Modulators of c3a receptors | |
| IL222313A0 (en) | Combination of organic compounds | |
| HRP20190476T1 (en) | Process for the preparation of histamine h3 receptor modulators | |
| PL2401253T3 (en) | A process for the preparation of etoricoxib | |
| HK1180955A1 (en) | Heterocyclyl compounds as histamine h3 receptor ligands h3 | |
| GB0908711D0 (en) | Preparation of labelled compounds | |
| GB0922023D0 (en) | Preparation of n-monofluoroalkyl compounds | |
| HK1171020A1 (en) | Process for preparation of pyrimidinylpyrazole compounds | |
| EP2537851A4 (en) | Process for preparation of b-glycoside compounds | |
| IL215022A0 (en) | Novel process for the preparation of enaminocarbonyl compounds | |
| EP2563748A4 (en) | Method of preparing alkene compound | |
| EP2768814A4 (en) | Novel non-steroidal compounds as androgen receptor modulators | |
| ZA201200879B (en) | Novel compounds as modulators of glucocorticoid receptors | |
| EP2546235A4 (en) | PROCESS FOR PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS | |
| AU2011904606A0 (en) | Modulators of C3a receptors | |
| ZA201208583B (en) | Process for the preparation of hydroquinones | |
| GB201021416D0 (en) | Novel heterocyclic compounds |